Clinical trial · Observational
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Improving Response Assessment in Cancer by Measurement of Cellular Redox Status Using 18F-FSPG Positron Emission Tomography
NCT05889312CI-TRIAL-00088173recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Diagnosis | — | UNRESOLVED | — |
| Resistant Cancer | — | UNRESOLVED | — |
| Response, Acute Phase | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FSPG PET/CT in HNSCC | Diagnostic Test | — | UNRESOLVED |
| 18F-FSPG PET/CT in NSCLC | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Non-small cell lung cancer
- description
- NSCLC
- interventionNames
- Diagnostic Test: 18F-FSPG PET/CT in NSCLC
- label
- Head and neck squamous cell cancer
- description
- HNSCC
- interventionNames
- Diagnostic Test: 18F-FSPG PET/CT in HNSCC
Primary outcomes (1)
- measure
- Changes in tumour cellular redox status
- timeFrame
- 3 years
- description
- To measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent 2. Aged 16 or above 3. Histologically confirmed HNSCC or NSCLC, who are treatment naïve and scheduled to commence standard of care treatment ((chemo)radiotherapy) 4. Willingness and ability to comply with scheduled study visits and tests 5. Confirmation of adequate function of all major organs and systems Exclusion Criteria: 1. Pregnant or lactating women 2. Concomitant uncontrolled medical conditions 3. Participants likely to require palliative radiotherapy within the first 12 weeks of treatment 4. Prognosis less than 3 months 5. Previous anti-cancer treatment (only treatment naïve patients eligible for inclusion)
References
Publications (0)
Data not yet available
No reference posted for this study.